3D Interactions with the Growth Hormone Locus in Cellular Signalling and Cancer-Related Pathways
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Genes Uniquely Expressed in Human Growth Plate Chondrocytes Uncover
Li et al. BMC Genomics (2017) 18:983 DOI 10.1186/s12864-017-4378-y RESEARCHARTICLE Open Access Genes uniquely expressed in human growth plate chondrocytes uncover a distinct regulatory network Bing Li1, Karthika Balasubramanian1, Deborah Krakow2,3,4 and Daniel H. Cohn1,2* Abstract Background: Chondrogenesis is the earliest stage of skeletal development and is a highly dynamic process, integrating the activities and functions of transcription factors, cell signaling molecules and extracellular matrix proteins. The molecular mechanisms underlying chondrogenesis have been extensively studied and multiple key regulators of this process have been identified. However, a genome-wide overview of the gene regulatory network in chondrogenesis has not been achieved. Results: In this study, employing RNA sequencing, we identified 332 protein coding genes and 34 long non-coding RNA (lncRNA) genes that are highly selectively expressed in human fetal growth plate chondrocytes. Among the protein coding genes, 32 genes were associated with 62 distinct human skeletal disorders and 153 genes were associated with skeletal defects in knockout mice, confirming their essential roles in skeletal formation. These gene products formed a comprehensive physical interaction network and participated in multiple cellular processes regulating skeletal development. The data also revealed 34 transcription factors and 11,334 distal enhancers that were uniquely active in chondrocytes, functioning as transcriptional regulators for the cartilage-selective genes. Conclusions: Our findings revealed a complex gene regulatory network controlling skeletal development whereby transcription factors, enhancers and lncRNAs participate in chondrogenesis by transcriptional regulation of key genes. Additionally, the cartilage-selective genes represent candidate genes for unsolved human skeletal disorders. -
Improved Detection of Gene Fusions by Applying Statistical Methods Reveals New Oncogenic RNA Cancer Drivers
bioRxiv preprint doi: https://doi.org/10.1101/659078; this version posted June 3, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Improved detection of gene fusions by applying statistical methods reveals new oncogenic RNA cancer drivers Roozbeh Dehghannasiri1, Donald Eric Freeman1,2, Milos Jordanski3, Gillian L. Hsieh1, Ana Damljanovic4, Erik Lehnert4, Julia Salzman1,2,5* Author affiliation 1Department of Biochemistry, Stanford University, Stanford, CA 94305 2Department of Biomedical Data Science, Stanford University, Stanford, CA 94305 3Department of Computer Science, University of Belgrade, Belgrade, Serbia 4Seven Bridges Genomics, Cambridge, MA 02142 5Stanford Cancer Institute, Stanford, CA 94305 *Corresponding author [email protected] Short Abstract: The extent to which gene fusions function as drivers of cancer remains a critical open question. Current algorithms do not sufficiently identify false-positive fusions arising during library preparation, sequencing, and alignment. Here, we introduce a new algorithm, DEEPEST, that uses statistical modeling to minimize false-positives while increasing the sensitivity of fusion detection. In 9,946 tumor RNA-sequencing datasets from The Cancer Genome Atlas (TCGA) across 33 tumor types, DEEPEST identifies 31,007 fusions, 30% more than identified by other methods, while calling ten-fold fewer false-positive fusions in non-transformed human tissues. We leverage the increased precision of DEEPEST to discover new cancer biology. For example, 888 new candidate oncogenes are identified based on over-representation in DEEPEST-Fusion calls, and 1,078 previously unreported fusions involving long intergenic noncoding RNAs partners, demonstrating a previously unappreciated prevalence and potential for function. -
Cisplatin Treatment of Testicular Cancer Patients Introduces Long-Term Changes in the Epigenome Cecilie Bucher-Johannessen1, Christian M
Bucher-Johannessen et al. Clinical Epigenetics (2019) 11:179 https://doi.org/10.1186/s13148-019-0764-4 RESEARCH Open Access Cisplatin treatment of testicular cancer patients introduces long-term changes in the epigenome Cecilie Bucher-Johannessen1, Christian M. Page2,3, Trine B. Haugen4 , Marcin W. Wojewodzic1, Sophie D. Fosså1,5,6, Tom Grotmol1, Hege S. Haugnes7,8† and Trine B. Rounge1,9*† Abstract Background: Cisplatin-based chemotherapy (CBCT) is part of standard treatment of several cancers. In testicular cancer (TC) survivors, an increased risk of developing metabolic syndrome (MetS) is observed. In this epigenome- wide association study, we investigated if CBCT relates to epigenetic changes (DNA methylation) and if epigenetic changes render individuals susceptible for developing MetS later in life. We analyzed methylation profiles, using the MethylationEPIC BeadChip, in samples collected ~ 16 years after treatment from 279 Norwegian TC survivors with known MetS status. Among the CBCT treated (n = 176) and non-treated (n = 103), 61 and 34 developed MetS, respectively. We used two linear regression models to identify if (i) CBCT results in epigenetic changes and (ii) epigenetic changes play a role in development of MetS. Then we investigated if these changes in (i) and (ii) links to genes, functional networks, and pathways related to MetS symptoms. Results: We identified 35 sites that were differentially methylated when comparing CBCT treated and untreated TC survivors. The PTK6–RAS–MAPk pathway was significantly enriched with these sites and infers a gene network of 13 genes with CACNA1D (involved in insulin release) as a network hub. We found nominal MetS-associations and a functional gene network with ABCG1 and NCF2 as network hubs. -
Decoding the Regulatory Landscape of Melanoma Reveals TEADS As Regulators of the Invasive Cell State
ARTICLE Received 15 Sep 2014 | Accepted 16 Feb 2015 | Published 9 Apr 2015 DOI: 10.1038/ncomms7683 OPEN Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state Annelien Verfaillie1,*, Hana Imrichova1,*, Zeynep Kalender Atak1,*, Michael Dewaele2,3, Florian Rambow2,3, Gert Hulselmans1, Valerie Christiaens1, Dmitry Svetlichnyy1, Flavie Luciani2,3, Laura Van den Mooter3,4, Sofie Claerhout3,4, Mark Fiers3, Fabrice Journe5, Ghanem-Elias Ghanem5, Carl Herrmann6, Georg Halder3,4, Jean-Christophe Marine2,3 & Stein Aerts1 Transcriptional reprogramming of proliferative melanoma cells into a phenotypically distinct invasive cell subpopulation is a critical event at the origin of metastatic spreading. Here we generate transcriptome, open chromatin and histone modification maps of melanoma cultures; and integrate this data with existing transcriptome and DNA methylation profiles from tumour biopsies to gain insight into the mechanisms underlying this key reprogramming event. This shows thousands of genomic regulatory regions underlying the proliferative and invasive states, identifying SOX10/MITF and AP-1/TEAD as regulators, respectively. Knockdown of TEADs shows a previously unrecognized role in the invasive gene network and establishes a causative link between these transcription factors, cell invasion and sensitivity to MAPK inhibitors. Using regulatory landscapes and in silico analysis, we show that transcriptional reprogramming underlies the distinct cellular states present in melanoma. Furthermore, it reveals an essential role for the TEADs, linking it to clinically relevant mechanisms such as invasion and resistance. 1 Laboratory of Computational Biology, Center for Human Genetics, University of Leuven, 3000 Leuven, Belgium. 2 Laboratory for Molecular Cancer Biology, Center for Human Genetics, University of Leuven, 3000 Leuven, Belgium. -
Lncrna-Mediated Regulation of SOX9 Expression in Basal Subtype Breast Cancer Cells
Downloaded from rnajournal.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press LncRNA-mediated regulation of SOX9 expression in basal subtype breast cancer cells AAMIRA TARIQ,1,2 QINYU HAO,2 QINYU SUN,2 DEEPAK K. SINGH,2 MAHDIEH JADALIHA,2 YANG ZHANG,3 NEHA CHETLANGIA,2 JIAN MA,3 SARAH E. HOLTON,4 ROHIT BHARGAVA,4 ASHISH LAL,5 SUPRIYA G. PRASANTH,2 and KANNANGANATTU V. PRASANTH2 1Department of Biosciences, Comsats Institute of Information Technology, Islamabad 45550, Pakistan 2Department of Cell and Developmental Biology, Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA 3Computational Biology Department, School of Computer Science, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA 4Department of Bioengineering and Beckman Institute of Advanced Science and Technology, Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA 5Regulatory RNAs and Cancer Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA ABSTRACT Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer (BC) subtypes with a poor prognosis and high recurrence rate. Recent studies have identified vital roles played by several lncRNAs (long noncoding RNAs) in BC pathobiology. Cell type-specific expression of lncRNAs and their potential role in regulating the expression of oncogenic and tumor suppressor genes have made them promising cancer drug targets. By performing a transcriptome screen in an isogenic TNBC/basal subtype BC progression cell line model, we recently reported ∼1800 lncRNAs that display aberrant expression during breast cancer progression. -
Lncrna-Mediated Regulation of SOX9 Expression in Basal Sub-Type 2 Breast Cancer Cells
Downloaded from rnajournal.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press 1 LncRNA-mediated regulation of SOX9 expression in basal sub-type 2 breast cancer cells 3 4 Aamira Tariq1,2*, Qinyu Hao2, Qinyu Sun2, Deepak K. Singh2, Mahdieh Jadaliha2, Yang 5 Zhang3, Neha Chetlangia2, Jian Ma3, Sarah E. Holton4, Rohit Bhargava4, Ashish Lal5, Supriya 6 G. Prasanth2, Kannanganattu V. Prasanth2* 7 8 1Department of Biosciences, Comsats Institute of Information Technology, Islamabad, 9 Pakistan 10 11 2Department of Cell and Developmental Biology, Cancer Center at Illinois, University of 12 Illinois at Urbana-Champaign, Urbana, IL, USA. 13 14 3Computational Biology Department, School of Computer Science, Carnegie Mellon 15 University, Pittsburgh, PA, USA. 16 17 4Department of Bioengineering and Beckman Institute of Advanced Science and 18 Technology, Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, 19 IL, USA. 20 21 5Regulatory RNAs and Cancer Section, Genetics Branch, Center for Cancer Research, 22 National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 23 24 Running title: LncRNA promotes breast cancer cell proliferation. 25 26 Key words: Nuclear lncRNA, Basal-like subtype, TNBC, Regulation, Enhancer 27 28 * Corresponding authors Tariq et al 1 Downloaded from rnajournal.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press 29 Aamira Tariq 30 Department of Biosciences, Comsats Institute of Information Technology, Islamabad, 31 Pakistan; Department